Vertex Pharmaceuticals Incorporated (VRTX)Healthcare | Biotechnology | Boston, United States | NasdaqGS
480.25 USD
-5.14
(-1.059%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 481.40 +1.15 (0.239%) ⇧ (July 13, 2026, 7:58 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:53 a.m. EDT
Vertex offers a compelling long-term investment thesis driven by exceptional profitability and a fortress balance sheet, highlighted by a 24% return on equity and robust free cash flow generation. Despite a recent single-year price dip, the nine-year cumulative gain remains substantial, and the forward valuation implies earnings acceleration is priced in. However, the absence of a dividend stream limits income appeal, and short-term sentiment is mixed with elevated option volatility and conflicting speculative positioning. The stock trades above key moving averages, supporting a cautious bullish stance for the near term, though the lack of sustained high-revenue growth prevents a top-tier long-term classification. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.036619 |
| AutoETS | 0.040027 |
| MSTL | 0.040103 |
| AutoARIMA | 0.043896 |
| MSTL_126 | 0.045860 |
| MSTL_90_126 | 0.053740 |
| MSTL_90 | 0.054499 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 9.99 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.21 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.26 |
| Revenue per Share | 47.914 |
| Market Cap | 121,890,054,144 |
| Trailing P/E | 28.83 |
| Forward P/E | 22.68 |
| Beta | 0.29 |
| Profit Margins | 35.51% |
| Website | https://www.vrtx.com |
As of July 11, 2026, 3:53 a.m. EDT: Implied volatility is elevated between 31% and 44%, reflecting market uncertainty. Open interest clusters suggest a bullish bias with significant call positioning above the 500 strike, while put open interest concentrates between 380 and 440. Recent flow indicates new call interest at 500-520 strikes alongside substantial put volume at 385-420 strikes, signaling a mix of speculative upside bets and protective hedging.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.027606606 |
| Address1 | 50 Northern Avenue |
| All Time High | 533.67 |
| All Time Low | 3.25 |
| Ask | 481.6 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 2,541,860 |
| Average Daily Volume3 Month | 1,498,104 |
| Average Volume | 1,498,104 |
| Average Volume10Days | 2,541,860 |
| Beta | 0.292 |
| Bid | 480.43 |
| Bid Size | 1 |
| Board Risk | 5 |
| Book Value | 76.179 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 480.25 |
| Current Ratio | 3.023 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 484.32 |
| Day Low | 474.71 |
| Debt To Equity | 10.26 |
| Earnings Call Timestamp End | 1,785,787,200 |
| Earnings Call Timestamp Start | 1,785,787,200 |
| Earnings Growth | 0.614 |
| Earnings Quarterly Growth | 0.596 |
| Earnings Timestamp | 1,785,787,200 |
| Earnings Timestamp End | 1,785,787,200 |
| Earnings Timestamp Start | 1,785,787,200 |
| Ebitda | 4,981,199,872 |
| Ebitda Margins | 0.40769002 |
| Enterprise To Ebitda | 23.414 |
| Enterprise To Revenue | 9.546 |
| Enterprise Value | 116,629,848,064 |
| Eps Current Year | 18.98323 |
| Eps Forward | 21.17837 |
| Eps Trailing Twelve Months | 16.66 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 454.3746 |
| Fifty Day Average Change | 25.875397 |
| Fifty Day Average Change Percent | 0.056947276 |
| Fifty Two Week Change Percent | 2.7606606 |
| Fifty Two Week High | 533.67 |
| Fifty Two Week High Change | -53.419983 |
| Fifty Two Week High Change Percent | -0.10009928 |
| Fifty Two Week Low | 362.5 |
| Fifty Two Week Low Change | 117.75 |
| Fifty Two Week Low Change Percent | 0.32482758 |
| Fifty Two Week Range | 362.5 - 533.67 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 680,362,200,000 |
| Float Shares | 253,071,919 |
| Forward Eps | 21.17837 |
| Forward P E | 22.67644 |
| Free Cashflow | 2,783,225,088 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 6,400 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.54390997 |
| Gross Profits | 6,645,499,904 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.002 |
| Held Percent Institutions | 0.97991997 |
| Implied Shares Outstanding | 253,805,417 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.vrtx.com/finances.html |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 967,075,200 |
| Last Split Factor | 2:1 |
| Long Business Summary | Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. |
| Long Name | Vertex Pharmaceuticals Incorporated |
| Market | us_market |
| Market Cap | 121,890,054,144 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_36235 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 4,338,299,904 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 123,194,611,357 |
| Number Of Analyst Opinions | 25 |
| Open | 482.6 |
| Operating Cashflow | 4,240,600,064 |
| Operating Margins | 0.38126 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.74 |
| Phone | 617 341 6100 |
| Post Market Change | 1.1499939 |
| Post Market Change Percent | 0.23945734 |
| Post Market Price | 481.4 |
| Post Market Time | 1,783,987,081 |
| Previous Close | 485.39 |
| Price Eps Current Year | 25.298645 |
| Price Hint | 2 |
| Price To Book | 6.3042307 |
| Price To Sales Trailing12 Months | 9.976269 |
| Profit Margins | 0.35507 |
| Quick Ratio | 2.382 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.63333 |
| Region | US |
| Regular Market Change | -5.14001 |
| Regular Market Change Percent | -1.05895 |
| Regular Market Day High | 484.32 |
| Regular Market Day Low | 474.71 |
| Regular Market Day Range | 474.71 - 484.32 |
| Regular Market Open | 482.6 |
| Regular Market Previous Close | 485.39 |
| Regular Market Price | 480.25 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,152,475 |
| Return On Assets | 0.12142 |
| Return On Equity | 0.24197 |
| Revenue Growth | 0.078 |
| Revenue Per Share | 47.914 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 253,805,417 |
| Shares Percent Shares Out | 0.0195 |
| Shares Short | 4,938,472 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,491,490 |
| Short Name | Vertex Pharmaceuticals Incorpor |
| Short Percent Of Float | 0.022 |
| Short Ratio | 2.71 |
| Source Interval | 15 |
| State | MA |
| Symbol | VRTX |
| Target High Price | 641.0 |
| Target Low Price | 350.0 |
| Target Mean Price | 556.96 |
| Target Median Price | 572.0 |
| Total Cash | 7,246,700,032 |
| Total Cash Per Share | 28.552 |
| Total Debt | 1,986,499,968 |
| Total Revenue | 12,218,000,384 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 16.66 |
| Trailing P E | 28.82653 |
| Trailing Peg Ratio | 1.7392 |
| Triggerable | 1 |
| Two Hundred Day Average | 446.88086 |
| Two Hundred Day Average Change | 33.36914 |
| Two Hundred Day Average Change Percent | 0.074671224 |
| Type Disp | Equity |
| Volume | 1,152,475 |
| Website | https://www.vrtx.com |
| Zip | 2,210 |